Objective: To determine the causative genetic lesion in 3 adult siblings with a slowly progressive, juvenile-onset phenotype comprising cerebellar atrophy and ataxia, intellectual decline, hearing loss, hypogonadism, hyperreflexia, a demyelinating sensorimotor neuropathy, and (in 2 of 3 probands) supratentorial white matter changes, in whom numerous prior investigations were nondiagnostic.
METHODS Standard protocol approvals, registrations, and patient consents. This study was approved by the McMaster University Research Ethics Board. Each participant (or legal guardian) signed an informed consent document before enrollment. Written consent to disclose health information was obtained from each individual.
Whole-exome sequencing and variant annotation. Total leukocyte DNA was enriched using the Agilent SureSelect Human All Exon 50 Mb capture kit (Agilent Technologies, Santa Clara, CA), and subjected to bidirectional 100-bp paired-end sequencing (Illumina Hi-Seq 2000; Illumina, Inc., San Diego, CA). Mean exon coverage was 134-1623, with .98% of target base positions having at least 103 coverage. Sequence reads were aligned to the hg19 reference human genome using Burrows-Wheeler Aligner (http://bio-bwa.sourceforge.net), and duplicate reads were removed with MarkDuplicates (Picard tools version 1.35; http://picard.sourceforge.net). Alignments were refined using local realignment in Short Read Micro re-Aligner version 0.1.15 (http://sourceforge.net/projects/srma). Single nucleotide variants and insertion/deletions were detected using Genome Analysis Toolkit version 1.1.28 (http://www.broadinstitute.org/gatk) with default parameters. Single nucleotide variants and insertion/deletions were annotated with SnpEff (http://snpeff.sourceforge.net/) and filtered to remove common (frequency .0.01) polymorphisms by screening against the following databases: dbSNP (http://www.ncbi.nlm.nih. gov/projects/SNP/); 1000 Genomes (www.1000genomes.org); the NHLBI Exome Variant Server (http://evs.gs.washington.edu/EVS/); and data from 130 local control exomes. Filtered variants were annotated with SIFT (http://sift-dna.org) and PolyPhen-2 (http:// genetics.bwh.harvard.edu/pph2/). Mutations were confirmed by Sanger sequencing according to standard protocols.
RESULTS
Clinical description. The patients were 3 adult siblings (2 women and 1 man) of nonconsanguineous Italian background, presenting with sensorineural hearing loss in middle childhood, followed by ataxia and progressive cognitive decline from adolescence onward. Clinical findings in these 3 individuals are summarized in table 1. Cranial MRI revealed marked cerebellar atrophy (figure 1); this was accompanied by a progressive peripheral neuropathy, with diminished deep tendon reflexes, reduced vibration sensation, and a demyelinating motor polyneuropathy on nerve conduction testing. Neuro-ophthalmic assessment, including dilated fundus examination, was normal. Symptoms were gradually progressive in all cases; however, the course of patient 2 was further complicated by episodes of left-sided weakness with abnormal eye movements and the appearance of multiple, gadolinium-enhancing white-matter lesions. These occurred in both infra-and supratentorial compartments, and in a pericallosal/periventricular distribution, including the presence of Dawson fingers. Oligoclonal bands were present in CSF; pulse steroids were given with a good initial response, and the patient was maintained on immunosuppressive therapy (initially with azathioprine, and later with fingolimod as newer agents became available). On follow-up imaging, the individual lesions exhibited interval evolution and contraction; however, there was a gradual overall (clinically more severe) shows an even greater degree of cerebellar atrophy, with additional cystic white matter lesions, thinned corpus callosum, and diffuse cerebral volume loss. Before this study, the patients underwent a panoply of diagnostic and laboratory investigations, none of which revealed a specific diagnosis. These included very long-chain fatty acids and phytanic acid in plasma (normal, genomic microarray, muscle biopsy) with full mitochondrial disease workup, and genetic testing for each of the following: spinocerebellar ataxia types 1, 2, 3, 6, 7, 8, and 17, Friedreich ataxia, autosomal recessive hereditary spastic paraplegias (CYP7B1, SPG11, SPG7, SPG15, PNPLA6, SPG20, SPG21, CCT5, and SPG44), and autosomal recessive spastic ataxia of Charlevoix-Saguenay.
Mutation identification. To identify the causative gene in this family, we conducted whole-exome sequencing at The Centre for Applied Genomics (see methods), revealing the presence of 2 rare, nonsynonymous coding variants in HSD17B4 in all 3 affected individuals. The specific mutations identified were Table 2 Peroxisomal investigations in blood and cultured fibroblasts (3) the presence of many of its key findings in other, relatively common, conditions. For instance, compatible symptoms may be seen in many of the spinocerebellar ataxias and in the complicated hereditary spastic paraplegias SPG7 (OMIM 607259), SPG20 (Troyer syndrome, OMIM 275900), and SPG21 (Mast syndrome, OMIM 248900), and in mitochondrial diseases. Given the low pretest probability for each of these disorders, exome-or panel-based molecular testing may indeed be the most practical initial test in patients with overlapping clinical presentations. White matter lesions, a variable feature in our patients, are a known sequela of classic DBP deficiency, with periventricular cerebral demyelination and callosal thinning reported to occur in 17% and 55% of cases, respectively. 2 As far as we are aware, white matter disease has not previously been reported in later (juvenile)-onset patients. The presence of CSF oligoclonal bands in patient 2 is interesting, especially considering the recent report of severe, chronic cerebral inflammation in knockout mice lacking DBP. 10 Whether this represents simple coincidence vs an autoimmune component to the disease process itself is unclear.
No proven treatments exist to address the underlying biochemical defect in this disorder, although dietary phytanic acid restriction and/or bile acid supplementation may warrant further study. Although our probands do not demonstrate phytanic acid accumulation in peripheral blood, concentrations in other tissues (e.g., CSF and brain tissue) are unknown. It is reasonable to suppose that juvenile-onset patients may possess a degree of residual enzyme activity in vivo; enhancing this (e.g., via chaperone therapy) is another possible approach. Although the number of reported patients is currently too few to permit clinical trials, the recognized prevalence of this disorder is likely to increase as exome sequencing enters the clinical mainstream.
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